Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
Projectdetails
Introduction
A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Parkinson’s disease (PD) is associated with tremor and loss of motor functions due to progressive degeneration of dopaminergic neurons in the brain.
Impact of Parkinson's Disease
This can lead to memory loss and dementia, which is associated with short- and long-term injuries and disabilities with emotional, financial, and social burdens for patients, families, and society. The exact causes and mechanisms underlying PD are still unknown, and existing treatments focus on alleviating symptoms and increasing quality of life, but do not halt or reverse disease progression.
Limitations of Current Research
Although animal models give unique possibilities to study physiological and behavioural mechanisms, drug development fails due to lack of translation to humans. Alternative non-animal NDD models are needed both in terms of better translation and to replace expensive and problematic animal experiments.
New Approach: Connectoids
We will move disease modelling to a new level and replace animal models by creating a new concept we call connectoids. We will develop an ex-vivo-type in vitro human opto-electronic multi-regional brain-organoid disease model in which connectoids are formed by precise spatial arrangement of brain organoids connected via hydrogel tracts that promote axonal pathfinding, functional connection, and signalling.
Technological Innovations
By developing:
- Light controllable sub-type specific neurons within regionalized brain organoids, and
- Electrodes and waveguides that can penetrate the organoids able to monitor neurotransmitter signalling inside and between the organoids,
we will for the first time be able to sense how a particular brain region responds to a certain therapy and watch in real time how signals are transmitted to other brain regions.
Conclusion
Our model will not only have health benefits, but will relieve a heavy economic burden on society and open up new possibilities for technological and economic development.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.992.203 |
Totale projectbegroting | € 2.992.203 |
Tijdlijn
Startdatum | 1-11-2022 |
Einddatum | 31-10-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DANMARKS TEKNISKE UNIVERSITETpenvoerder
- LUNDS UNIVERSITET
- UNIVERSIDAD AUTONOMA DE MADRID
- BICO GROUP AB
- CELLINK BIOPRINTING AB
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analyticsThe 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders. | EIC Pathfinder | € 1.998.347 | 2023 | Details |
Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analytics
The 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotencyThe project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Engineering human cortical brain organoid’s connections to restore brain functionsThis project aims to restore functional neuronal networks in cortical brain lesions using 3D bioprinted human-specific hydrogels and cortical brain organoids for innovative therapeutic solutions. | ERC Starting... | € 1.500.000 | 2024 | Details |
Bidirectional Brain/Neural-Computer Interaction for Restoration of Mental HealthThis project aims to develop a portable neuromodulation system using quantum sensors and magnetic stimulation to precisely target brain oscillations for treating mental health disorders. | ERC Consolid... | € 1.999.875 | 2025 | Details |
An automated platform for the large-scale production of miniaturized neuromuscular organoidsThe project aims to automate and scale the production of complex neuromuscular organoids for high-throughput drug screening to advance therapies for neuromuscular diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
Human skeletal muscle platform for disease modelling and high-throughput drug screeningDeveloping a high-throughput in vitro platform with biomimetic skeletal muscle analogues to model neuromuscular disorders for effective drug screening and therapy validation. | ERC Proof of... | € 150.000 | 2023 | Details |
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency
The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.
Engineering human cortical brain organoid’s connections to restore brain functions
This project aims to restore functional neuronal networks in cortical brain lesions using 3D bioprinted human-specific hydrogels and cortical brain organoids for innovative therapeutic solutions.
Bidirectional Brain/Neural-Computer Interaction for Restoration of Mental Health
This project aims to develop a portable neuromodulation system using quantum sensors and magnetic stimulation to precisely target brain oscillations for treating mental health disorders.
An automated platform for the large-scale production of miniaturized neuromuscular organoids
The project aims to automate and scale the production of complex neuromuscular organoids for high-throughput drug screening to advance therapies for neuromuscular diseases.
Human skeletal muscle platform for disease modelling and high-throughput drug screening
Developing a high-throughput in vitro platform with biomimetic skeletal muscle analogues to model neuromuscular disorders for effective drug screening and therapy validation.